Jaguar Health shares plunge 13.65% as MVID trial enters extension phase
AI Summary- Jaguar Health’s Napo Pharmaceuticals advanced all randomized pediatric MVID patients into a single-blind extension.
- 13.65%: JAGX shares fell to 31 cents Thursday, reaching a new 52-week low.
- Mid-2027: Jaguar targets a New Drug Application filing with the U.S. Food and Drug Administration.